Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
NextCell Pharma AB's ("NextCell" or the "Company") CSO, Dr Lindsay Davies, has been invited to give a presentation at the EWMA meeting in Milan, showcasing NextCell's phase II clinical data with their investigative medicinal product, ProTrans, in slowing the progression of type-1 diabetes.
Dr Davies, in addition to her role at NextCell, is a member of the scientific advisory board for the European Tissue Repair Society (ETRS). ETRS and EWMA have partnered for a session at the annual conference, that brings together wound management researchers, clinicians and industrial partners to discuss innovative therapies and treatment options for wound patients.
Dr Davies has been invited to speak at the conference on 4[th] May. Her presentation is entitled, "Mesenchymal stromal cells - a novel approach to the treatment of type 1 diabetes". The meeting will be held at MICo Milano Convention Centre, Milan, Italy, from Wednesday 3[rd] to Friday 5[th] of May.